产品
编 号：F749868
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2213450-26-9
产品详情
生物活性：
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC).
体内研究：
MCLA-158 (25 mg/kg/周，静脉注射，持续 6 周) 导致食管鳞癌、胃腺癌和头颈部 PDX 模型的肿瘤消退。Animal Model:Esophageal squamous, gastric adenocarcinoma and head & neck PDX models
Dosage:25 mg/kg/week
Administration:Intravenous injection (i.v.) for 6 weeks.
Result:Inhibited tumor growth.
体外研究：
MCLA-158 (1 μg/mL，24 或 72 小时) 导致 EGFR+/LGR5+ 结直肠癌类器官中的 EGFR 降解。
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC).
体内研究：
MCLA-158 (25 mg/kg/周，静脉注射，持续 6 周) 导致食管鳞癌、胃腺癌和头颈部 PDX 模型的肿瘤消退。Animal Model:Esophageal squamous, gastric adenocarcinoma and head & neck PDX models
Dosage:25 mg/kg/week
Administration:Intravenous injection (i.v.) for 6 weeks.
Result:Inhibited tumor growth.
体外研究：
MCLA-158 (1 μg/mL，24 或 72 小时) 导致 EGFR+/LGR5+ 结直肠癌类器官中的 EGFR 降解。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备